GPBAR1 and neoplasm: Its canonical anti-inflammatory pathway contrasts with context-specific or biased signaling mechanisms that can contribute to either tumor suppression or promotion, highlighting the critical need to understand these nuances when considering TGR5 as a therapeutic target.